STRATA Skin Sciences Announces Preliminary Fourth Quarter 2020 Economic Effects and …

Preliminary, unaudited fourth quarter revenues in the vary of $6.6 million to $6.8 million 

Preliminary, unaudited fourth quarter recurring revenues in the range of $5. million to $5.2 million

Throughout the world installed foundation elevated by 23 placements in the fourth quarter

HORSHAM, Pa., Jan. 12, 2021 (Globe NEWSWIRE) — STRATA Skin Sciences, Inc. (NASDAQ: SSKN) a medical technologies business in dermatology and plastic surgery focused to establishing, commercializing, and marketing progressive merchandise for the cure of dermatologic disorders, these days documented preliminary, unaudited fourth quarter 2020 economical results and vital operational metrics.

Fourth Quarter Economical Highlights

• Preliminary, unaudited complete income is predicted to vary from $6.6 million to $6.8 million, in comparison to $8.9 million in the fourth quarter of 2019 and $5.6 million in the 3rd quarter of 2020
• Preliminary, unaudited recurring earnings is envisioned to assortment from $5. million to $5.2 million, in contrast to $6.6 million in the fourth quarter of 2019 and $3.8 million in the 3rd quarter of 2020
• Preliminary unaudited gross domestic recurring billings are predicted to range from $5.2 million to $5.4 million, when compared to $6.9 million in the fourth quarter of 2019 and $4.7 million in the 3rd quarter of 2020. (Reference this Non-GAAP measure beneath)
• Dollars and income equivalents, which includes restricted cash was $18. million as of December 31, 2020, in contrast to $15.6 million as of December 31, 2019

Fourth Quarter Operational Highlights

• Put 33 domestic XTRAC units and taken off 14, ensuing in net methods placed in domestic dermatologists’ workplaces of 19, of which 12 are comebacks from past excimer product proprietors
• Positioned 4 additional XTRAC systems in worldwide marketplaces, together with the very first recurring profits process in Japan
• Overall XTRAC methods positioned domestically arrived at 832 as of December 31, 2020, compared to 820 devices as of December 31, 2019
• Whole XTRAC devices put internationally achieved 28 as of December 31, 2020, compared to 10 as of December 31, 2019
• Renewed money secured take note payable by means of December 30, 2021

Dr. Dolev Rafaeli, STRATA Skin Sciences’ President and CEO mentioned, “Our fourth quarter started off incredibly powerful with Oct 2020 gross domestic recurring billings at 97% of the identical period in 2019. Nonetheless, we saw this development start off to taper off in the 2nd half of November because of to the continued escalation of COVID-19 and the subsequent renewed continue to be at home orders. Encouragingly, our December results in the end reflected the best gross domestic billing month of 2020. Over-all, we are happy with the sequential profits progress we professional in excess of the third quarter, as this presents us with a sturdy base to enter 2021.”

The preliminary unaudited results explained in this press launch are estimates only and are issue to revision right until the Organization stories its total financial results for the year ended December 31, 2020 which is anticipated in late March.

Non-GAAP Measure

To dietary supplement the Company’s consolidated economical statements, prepared in accordance with accounting ideas frequently recognized in the United States of America (“GAAP”), the Company presents the non-GAAP evaluate of money efficiency, Gross Domestic Recurring Billings.

The Company’s reference to these non-GAAP steps should be viewed as in addition to final results well prepared less than latest accounting expectations, but is not a substitute for, nor remarkable to, GAAP final results. These non-GAAP measures are supplied to enrich investors’ total being familiar with of our recent economic efficiency and to give further more data for comparative purposes.

Particularly, the Enterprise thinks the non-GAAP steps deliver valuable information to both administration and traders by isolating profits and deferred earnings impacts that might not be indicative of the Company’s core functioning benefits and company outlook. In addition, the Enterprise believes non-GAAP actions enrich the comparability of final results versus prior periods.

Gross Domestic Recurring Billings

Gross domestic recurring billings represent the volume invoiced to associate clinics in the United States when remedy codes are bought to the doctor. It does not include regular GAAP adjustments which are deferred earnings from prior quarters recorded as profits in the latest quarter, the deferral of profits from the latest quarter recorded as income in future quarters, adjustments for co-pay out and other discounts. This excludes worldwide recurring revenues.

The reconciliation to non-GAAP gross domestic recurring billings to anticipated domestic recurring recorded profits for the fourth quarter is made up of the following: predicted gross domestic recurring billings of between $5.2 million and $5.4 million, minimized by envisioned co-pay out and credits of in between $50 thousand and $150 thousand, improved by deferred income from the third quarter of $1.4 million, and diminished by envisioned deferral of income to long term quarters of amongst $1.6 million and $1.8 million, ensuing in expected domestic recurring recorded revenue of amongst $4.8 million and $5. million.

About STRATA Skin Sciences, Inc. ( www.strataskinsciences.com )        
STRATA Pores and skin Sciences is a clinical technology corporation in dermatology and plastic operation committed to establishing, commercializing and marketing progressive goods for the treatment of dermatologic ailments. Its products contain the XTRAC® excimer laser and VTRAC® lamp devices utilized in the treatment method of psoriasis, vitiligo and different other pores and skin circumstances.

The Company’s proprietary XTRAC® excimer laser provides a highly targeted therapeutic beam of UVB gentle to deal with psoriasis, vitiligo, eczema, atopic dermatitis and leukoderma, illnesses which influence about 35 million clients in the United States by yourself. The know-how is coated by numerous patents, such as unique legal rights for patents for the delivery of treatment method to vitiligo people.

STRATA’s special organization product leverages qualified Immediate to Customer (DTC) promotion to deliver awareness and makes use of its in-home call middle and insurance coverage advocacy teams to raise quantity for the Company’s husband or wife dermatology clinics.

The XTRAC business enterprise has used this verified DTC design to improve its domestic dermatology companion network to more than 832 clinics, with a around the world put in foundation of over 2,000 products. The Firm is in a position to provide 90% of DTC clients an introduction to medical professionals prescribing a reimbursable remedy, utilizing XTRAC, within just a 10-mile radius of their household. The Corporation is a chief in dermatology in-clinic enterprise technology for its partners.

The Firm has now introduced its Property by XTRAC™ small business leveraging in-home assets such as DTC advertising and marketing, in-household simply call center and its insurance policies reimbursement staff to supply an at-property, insurance policies-reimbursed treatment method selection for sufferers with particular skin illnesses that do not qualify for in-office treatments.

Safe Harbor

This press release involves “forward-searching statements” within just the this means of the Securities Litigation Reform Act of 1995. These statements consist of but are not confined to the Company’s plans, objectives, expectations and intentions and might include words and phrases such as “will,” “may,” “seeks,” and “expects,” that suggest long term events or traits. These statements, the Company’s capacity to crank out the expansion in its main organization, the Company’s potential to produce social media promoting strategies, the Company’s means to build a foremost franchise in dermatology and aesthetics, the Company’s ability to create a organization for property-centered treatment method of skin health conditions, are dependent on the Company’s present-day expectations and are inherently subject to considerable uncertainties and changes in instances. True benefits could vary materially from the Company’s expectations because of to fiscal, economic, small business, competitive, marketplace, regulatory, adverse sector conditions or supply chain interruptions ensuing from the coronavirus and political factors or problems affecting the Corporation and the healthcare unit business in normal, upcoming responses to and effects of COVID-19 pandemic, as effectively as far more unique threats and uncertainties set forth in the Company’s SEC reports on Varieties 10-Q and 10-K. Given such uncertainties, any or all these forward-hunting statements may possibly verify to be incorrect or unreliable. The statements in this push release are built as of the day of this press release, even if subsequently produced available by the Corporation on its web-site or if not. The Firm does not undertake any obligation to update or revise these statements to mirror events or situations taking place immediately after the date of this push launch. The Organization urges investors to cautiously assessment its SEC disclosures readily available at  www.sec.gov  and  www.strataskinsciences.com.

Investor Contacts: